Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab

Hippokratia

Volumn 17, Issue 1, 2013, Pages 91-93

  Gigi, Eleni ^a   Georgiou, T ^a   Sarantopoulos, A ^a   Mougiou, D ^a   Boura, P ^a   Raptopoulou Gigi, M ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

HBV reactivation; Monoclonal antibodies; Rheumatoid arthritis; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN; ENTECAVIR; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; VIRUS DNA;

ADULT; ARTICLE; CASE REPORT; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; RHEUMATOID ARTHRITIS; VIRUS REACTIVATION;

EID: 84879702684     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Lavanchy D. Hepatitis B epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11: 97-107.
2. MacMahon BJ. Epidemiology and natural history of hepatitis B. Sem Liver Dis, 2005; 25 Suppl 1:3-8.
3. Guennoc X, Narbonne V, Jousse-Joulin S, Devauchelle-Pensec V, Douqados M, Daurès JP, et al. Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? The ESPOIR cohort study. J Rheumatol. 2009; 36: 1407-1413.
4. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43: 209-220.
5. Sorrel MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM et al. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis B. Ann Int Med. 2009; 150: 104-110.
6. Mastroianni CM, Lichter M, Citton R, Del Bolgo C, Rago A, Martini H, et al. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastrenterol. 2011; 34: 3881-3887.
7. Koo YX, Tay M, Tec YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011; 90: 1219-1223.
8. Kusumoto S, Tanaka Y, Ueda R, Mizokami M. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy. J Gastroenterol. 2011; 46: 9-16.
9. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007; 136: 699-712.
10. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al: Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011; 70: 909-920.
11. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008; 2: 152-162.
12. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative disease: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011; 22: 1170-1180.
13. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-185.